• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Chem Lab Med . IFCC interim guidelines on molecular testing of SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Clin Chem Lab Med


. 2020 Oct 7;/j/cclm.ahead-of-print/cclm-2020-1412/cclm-2020-1412.xml.
doi: 10.1515/cclm-2020-1412. Online ahead of print.
IFCC interim guidelines on molecular testing of SARS-CoV-2 infection


Mary Kathryn Bohn[SUP] 1 2 [/SUP], Nicasio Mancini[SUP] 3 [/SUP], Tze Ping Loh[SUP] 4 [/SUP], Cheng-Bin Wang[SUP] 5 [/SUP], Matthias Grimmler[SUP] 6 [/SUP], Maurizio Gramegna[SUP] 7 [/SUP], Kwok-Yung Yuen[SUP] 8 [/SUP], Robert Mueller[SUP] 9 [/SUP], David Koch[SUP] 10 [/SUP], Sunil Sethi[SUP] 4 [/SUP], William D Rawlinson[SUP] 11 [/SUP], Massimo Clementi[SUP] 3 [/SUP], Rajiv Erasmus[SUP] 12 [/SUP], Marc Leportier[SUP] 13 [/SUP], Gye Cheol Kwon[SUP] 14 [/SUP], Mar?a Elizabeth Menezes[SUP] 15 [/SUP], Maria-Magdalena Patru[SUP] 16 [/SUP], Krishna Singh[SUP] 17 [/SUP], Maurizio Ferrari[SUP] 3 [/SUP], Osama Najjar[SUP] 18 [/SUP], Andrea Horvath[SUP] 19 [/SUP], Khosrow Adeli[SUP] 1 2 [/SUP], Giuseppe Lippi[SUP] 20 21 [/SUP]



Affiliations

Abstract

The diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection globally has relied extensively on molecular testing, contributing vitally to case identification, isolation, contact tracing, and rationalization of infection control measures during the coronavirus disease 2019 (COVID-19) pandemic. Clinical laboratories have thus needed to verify newly developed molecular tests and increase testing capacity at an unprecedented rate. As the COVID-19 pandemic continues to pose a global health threat, laboratories continue to encounter challenges in the selection, verification, and interpretation of these tests. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay verification, and (D) test interpretation and limitations for molecular testing of SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide and highlight the continued importance of laboratory medicine in our collective pandemic response.

Keywords: COVID-19; SARS-CoV-2; molecular testing; virology.
 
Back
Top Bottom